|
業務類別
|
Biotechnology |
|
業務概覽
|
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cellactivation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment. |
| 公司地址
| 901 Gateway Boulevard, Third Floor, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 650 900-4520 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.corvuspharma.com |
| 員工數量
| 37 |
| Mr. Leiv Lea |
Chief Financial Officer and Principal Accounting Officer |
美元 405.95K |
24/04/2026 |
| Dr. Richard A. Miller,M.D. |
President, Chief Executive Officer and Chairman of the Board |
美元 36.57K |
24/04/2026 |
| Mr. Jeffrey Arcara |
Senior Vice President and Chief Business Officer |
-- |
24/04/2026 |
| Mr. William Benton Jones |
Senior Vice President, Pharmaceutical Development |
美元 360.12K |
24/04/2026 |
|
|
| Mr. Richard A. van den Broek |
Independent Director |
24/04/2026 |
| Mr. Ian T. Clark |
Independent Director |
24/04/2026 |
| Dr. Peter A. Thompson,M.D.,F.A.C.P. |
Independent Director |
24/04/2026 |
| Dr. Linda S. Grais, J.D.,M.D. |
Independent Director |
24/04/2026 |
| Dr. Richard A. Miller,M.D. |
President, Chief Executive Officer and Chairman of the Board |
24/04/2026 |
| Mr. David Moore |
Independent Director |
24/04/2026 |
| Dr. Andrew C. Chan, M.D.,PhD |
Director |
23/04/2026 |
|
|
|
|
